Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Down – Should You Sell?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) shares gapped down prior to trading on Tuesday. The stock had previously closed at $48.16, but opened at $42.90. Swedish Orphan Biovitrum shares last traded at $42.90, with a volume of 150 shares trading hands.

Wall Street Analysts Forecast Growth

BIOVF has been the subject of several recent analyst reports. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Swedish Orphan Biovitrum currently has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The company has a 50-day moving average of $48.25 and a 200-day moving average of $46.18. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. The stock has a market cap of $15.27 billion, a price-to-earnings ratio of 95.34 and a beta of 0.33.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.

Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.